Novo Nordisk’s Power Play: Ending Wegovy Shortages and Reshaping Pharma’s Future

Novo Nordisk is playing chess while the rest of the pharma industry wrestles with checkers. In a deal that could reshape drug manufacturing, Novo’s acquisition of three specialized Catalent facilities aims to end the crippling shortages of its obesity blockbuster Wegovy and diabetes giant Ozempic—and in the process, it’s forcing competitors to rethink their own supply chains​.

Here’s how the deal breaks down: Novo Holdings, Novo Nordisk’s controlling shareholder, is buying Catalent—one of the largest contract manufacturers—for $16.5 billion. Then, Novo Nordisk itself will purchase three Catalent plants for $11 billion, gaining critical production capacity for its surging obesity and diabetes drugs​. On paper, it’s a clean fix for a big headache: demand for Novo’s weight-loss injectables has far outstripped supply. In reality, it’s a seismic shift for the broader industry.

Why? Catalent isn’t just any contractor—it produces 1 in 28 drug doses worldwide and has worked on over half of the FDA-approved drugs in the past decade. Now, competitors like Eli Lilly, whose Zepbound and Mounjaro compete directly with Wegovy and Ozempic, find themselves in an awkward spot: relying on a contract manufacturer owned by their biggest rival​. Lilly, for its part, insists it isn’t worried. “Our primary strategy is self-run sites,” CEO David Ricks noted, adding that Lilly is aggressively building out its own manufacturing​.

Other industry leaders, like Roche, are treading carefully. CEO Thomas Schinecker previously warned that consolidation among contract manufacturers could hurt smaller players, raising concerns about competition and pricing power in the market​.

For Novo, this deal isn’t just about scaling up production—it’s about locking in control. The obesity drug market, valued at billions and growing fast, is Novo’s golden goose. Competitors are hot on its heels, but with exclusive access to specialized manufacturing and a clear path to meet skyrocketing demand, Novo just put a significant gap between itself and the field.

The question now is: Will rivals respond by bringing manufacturing in-house, or will regulators step in to scrutinize industry consolidation? Either way, Novo Nordisk’s move is more than a solution to supply issues—it’s a wake-up call for an industry that has leaned heavily on outsourced production.
​